VEGFA and neoplasm: For example, anti-VEGF therapies, such as bevacizumab, can lead to tumors adaptation by exploiting alternative angiogenic factors and recruiting myeloid derived suppressor cells (MDSCs) to promote angiogenesis [2], resulting in resistance to these therapies and potentially the emergence of tumor cells with a more aggressive phenotype [3], [4].